Equillium (EQ) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Equillium (EQ) has outperformed Upstream Bio (UPB) over the past year, gaining 10.4% versus a loss of 93.8%. Equillium is the larger company by market cap ($87.3 million vs $87.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | UPB |
|---|---|---|
| Share price | $1.06 | $1.59 |
| Market cap | $87.26M | $87.15M |
| 1-day change | -5.36% | -20.50% |
| YTD return | -31.61% | -94.14% |
| 1-year return | +10.42% | -93.78% |
| 5-year return | -80.41% | — |
| EPS (TTM) | $-0.12 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-22.40M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $3.54 | $33.68 |
| 52-week low | $0.81 | $1.56 |
| Distance from 52-week high | -70.06% | -95.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +707.55% | +1245.91% |
| Average volume | 544.39K | 1.01M |
| Shares outstanding | 82.32M | 54.81M |
| Employees | 14 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed UPB by 104.2 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
EQ vs UPB FAQ
Which is bigger, Equillium or Upstream Bio?
Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $87.15M for Upstream Bio (UPB).
Which stock has performed better over the past year, EQ or UPB?
EQ returned +10.42% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.